RIP2 expression correlated with the tumor size, metastasis, overall staging, progression-free survival, and body mass index (BMI) of patients with breast cancer, and RIPK2 polymorphism was also involved in the development of bladder cancer [14,15]. Here, RIPK2 is linked to neoplasm.